Nanobiotix SA (XPAR:NANO)
€ 4.86 -0.122 (-2.45%) Market Cap: 230.39 Mil Enterprise Value: 205.67 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q4 2021 Nanobiotix SA Earnings Call Transcript

Mar 31, 2022 / 12:00PM GMT
Release Date Price: €6.64 (-2.64%)
Operator

Good afternoon and good morning, and welcome to Nanobiotix conference call to discuss our 2021 full-year financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder and Chief Executive Officer; and Bart Van Rhijn, Chief Financial Officer.

As a reminder, today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success and timing of our ongoing and planned clinical trial collaboration, regulatory filing, data presentation and future research and development efforts, among other things.

These forward-looking statements are based on current information assumptions and expectations that are subject to change. They are subject to significant risks and uncertainties that could cause the company's actual results to differ materially from our current expectations.

Accordingly, you're cautioned not to place undue reliance on forward-looking statements. Please review the full description of risk factors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot